Though medical therapy is used in patients with symptomatic primary myelofibrosis (MF) to correct cytopenias and halt the progression of splenomegaly, it does not alter the natural history of MF.
1 Hematopoietic stem-cell transplantation (HSCT) is the only potentially curative therapy available but is associated with high transplantrelated morbidity and TRM. 2 The Lille scoring system created by Dupriez has helped identify intermediate-and higher-risk patients as candidates for HSCT 3 but despite rigorous patient selection, myeloablative protocols have been associated with high TRM rates. Reduced intensity conditioning (RIC) regimens have greatly increased interest in HSCT for myelofibrosis with survival rates of 60-90% being reported. [4] [5] [6] [7] [8] We performed a retrospective analysis of patients who underwent RIC allogeneic HSCT for MF at our center.
Between 2006 and 2007, six patients (three males and three females) with a median age of 51.4 years (range: 40-56 years) underwent RIC HSCT for MF (Table 1) . Five patients had primary MF whereas one developed MF 20 years after diagnosis of essential thrombocythemia. The median time from diagnosis to HSCT was 25 months (range: 10-243 months). Three patients each had a Lille Risk scoring system score of 1 or 2. Cytogenetic analysis showed a normal or a complex karyotype in two patients each, whereas one had a t(4;13) translocation and another had inadequate metaphases. Mutation analysis for the Janus Kinase 2 (Jak 2) V617F mutation by PCR was positive in two out of three patients tested.
Donors were either 6/6 antigen HLA-matched sibling (n ¼ 4) or 8/8 antigen-matched unrelated donors (n ¼ 2). Conditioning regimen included fludarabine (25 mg/m 2 /day i.v. for 6 days), busulfan (1 mg/kg PO QID for 10 doses) and antithymocyte globulin-fresenius (10-20 mg/kg/day i.v. for 3 days). G-CSF stimulated PBSCs were used in all. GVHD prophylaxis included intravenous cyclosporine (3 mg/kg/day) starting day À1 and short course intravenous methotrexate (10 mg/m 2 on days þ 1, þ 3 and þ 6). All CMV seropositive patients received pre-transplant ganciclovir for 8 days from day À10 to day À2. Valaciclovir and fluconazole were started on the day of transplant. No antibacterial prophylaxis was given pre-transplant, whereas bactrim prophylaxis against pneumocystis jiroveci, along with oral penicillin, was started by day 35 once WBC count was 43 Â 10 9 /l with ANC 41.5 Â 10 9 /l. Serial monitoring using CMV PCR was started by day þ 30 and pre-emptive therapy with either ganciclovir or foscarnet was instituted if required. Bone marrow analysis and whole blood chimerism using a variable number of tandem repeats (VNTRs) were done on day 30 post HSCT.
Median PBSC cell dose infused was 8.1 Â 10 6 CD34/kg (range: 2.4-10.5). Engraftment occurred in all at a median time to ANC 40.5 Â 10 9 /l of 19 days (range: 17-24) and platelet count 420 Â 10 9 /l of 26 days (range: 19-157). One patient with pre-existing anti-HLA platelet antibodies had delayed platelet engraftment by day 157. Two patients had Grade 3-4 mucositis whereas veno-occlusive disease of the liver was seen in none. One patient developed steroid responsive grade II acute GVHD on day 32. Two patients (33.3%) had documented bacterial infections, whereas another two had CMV reactivation that resolved completely with treatment. Bone marrow analysis at day 30 demonstrated complete absence of marrow fibrosis in two patients. Of the three patients with abnormal cytogenetics, two showed a complete cytogenetic response by day 30, whereas one had 85% reduction in the number of abnormal metaphases. Both patients who were JAK 2 positive became negative after HSCT. Day 30 chimerism analysis showed complete or mixed chimerism (80-90% donor) in three patients each. All patients with mixed chimerism have a stable mixed chimerism (donor cells 490%) at a median follow up of 16 months (range: 12-24 months). At a median follow up of 16.5 months (range: 10-24 months), all are alive and well.
The success of RIC transplants in older patients with leukemia has led to its use in other hematological disorders, such as myelofibrosis, where a few series suggest that RIC transplants were effective in achieving long-term disease control in a significant proportion of patients with MF with an acceptable toxicity. [4] [5] [6] [7] [8] All our patients had intermediateto high-risk Lille scores with three showing cytogenetic abnormalities. The use of an RIC regimen was associated with prompt engraftment and no primary graft failure with a low incidence of grade IV mucositis and no major regimen-related toxicity or significant GVHD. Two patients showed complete resolution of marrow fibrosis by day 30, suggesting that along with hematological remission, there was morphological remission in the marrow. An earlier study using an RIC regimen reported regression of bone marrow fibrosis in 59% by day 100 and 100% by day 360. 9 The majority of our patients who had either cytogenetic or molecular abnormalities achieved cytogenetic or molecular remission. Mixed chimerism by day 30, seen in 50% of our patients, may have resulted in the low incidence of acute GVHD in our series. An earlier study in RIC transplants suggested that the early establishment of full donor T-cell chimerism is associated with a higher incidence of grade 2-4 GVHD. 10 A longer follow-up of these patients is required to look for establishment of complete donor reconstitution. All patients are alive and well at a median follow-up of 16 months. These results are very encouraging considering that the mean age of these patients was 51 years and that all had either intermediate or high-risk disease. Though a longer follow up is required to predict long-term survival, the minimal toxicity, lack of TRM and the shorter duration of initial hospital stay makes it a very promising regimen.
In conclusion, the use of RIC regimens in myelofibrosis is associated with prompt engraftment, low incidence of GVHD and TRM and an excellent survival. A longer duration of follow-up is required, however, to evaluate the long-term outcome of RIC transplants in patients with myelofibrosis. 
